Today’s news is real progress. This approval allows people more options and greater opportunity to have more time.
Breaking News: The FDA has granted approval of Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We celebrate Kisunla’s approval as more options mean greater opportunity for more time. This is the third approval of an Alzheimer’s treatment that changes the underlying course of the disease. bit.ly/3XIyyvf
Dr Boris Nikolov
1mo
I think we need to continue looking actively into more options
Mary D.
1mo
Wonderful news, however the average person cannot afford it and we all know insurance companies are all about profits so they probably won't be much help.
Douglas Perry
1mo
2 by 2 table: box1 people who never got Alzheimer’s and never developed plaque, box 2 got plaque but no Alzheimer’s, box 3 got Alzheimer’s but no plaque, box 4 got both. If you followed 100 people born in 1950 to life expectancy, how many would be placed in each box at the end?
Bob Sliva
1mo
Forget the Easter egg…. don’t cancel Edge production. Big mistake vacating this segment. Look at the imports and what SUVs are selling. Explorer and Escape, while nice vehicles, won’t fill the void. My wife has driven 6 different Edges. Currently has an ST…not an STLine. ready to put Ford in the rear view mirror.
Maybe stop prescribing so many toxic pharmaceuticals and lead people back to health through organic nutrition, pure water, and moderate exercise. Also stop already with the toxic flu shots and other clot shots.
Jerry Jones
1mo
Joanne, this is incredible news and my initial thought when reading your post was "how might we increase access to those from marginalized and minoritized communities who are typically shut out from medical advances just like this?" and then see you called the same question in the press release. Any potential strategies the Association is considering to remove the barriers to trial participation?
Patrick Cawley
1mo
Very encouraging, especially with advancing technology for early detection. That will be the key. And your professional partners working with older adults will emphasize early detection.
Jonathan Jones
1mo
What is everyone's thoughts on Dean Ornish, M.D. of the Preventive Medicine Research Institute, lifestyle change methods? I saw the CNN special and I loved it.
Steven Taylor
1mo
Wonderful news. No matter what, more options make payers and others, start to pay attention and increase access. I know the Alzheimer’s Association is actively working and pushing for better access and affordability for treatments. Congrats Joanne and thanks for all the hard work on behalf of all patient groups who have access treatment barriers!
Former Director of Research - Center for Applied Research in Dementia now Consultant
1moThis is tragic news. The amyloid hypothesis has been and continues to be an abject failure. If you look at the actual data it becomes obvious that while the drug removes amyloid it does not cure anything. In addition, the results do NOT indicate that the drug will produce noticeable real world effects. Anyone trained in research will tell you that statistical significance does NOT equate with Clinical significance, as is the case with this drug. The Association does not mention that in addition to brain swelling and bleeding the drug and others in this class produce Shrinkage in brain volume over time. If the Association was truly interested in giving “more good days” to persons with dementia they should advocate that Medicare pay for hearing aids and glasses, not this latest boondoggle.